2026 real-world study: 84.4% of cancer patients taking ivermectin and mebendazole reported clinical benefit at 6 months, with nearly half seeing tumor reduction.
Preprint report on 197 cancer patients prescribed compounded ivermectin and mebendazole shows 84.4% clinical benefit ratio at 6 months, with key limitations noted.
Methylene blue, an FDA-approved drug for methemoglobinemia, is being studied in preclinical cancer research for its redox-cycling, ROS, and PDT mechanisms.
Rates of 14 cancer types are rising in adults under 50, with the sharpest jumps in the 20-29 age group. Researchers blame overlapping lifestyle and environmental factors.
Mayo Clinic’s REDMOD AI flags pancreatic cancer on routine CT scans up to 3 years before diagnosis, identifying 73% of cases vs. 39% for specialists alone.
